Coxsackievirus A10 (CVA10) has emerged worldwide as one of the main pathogens of hand, foot, and mouth disease (HFMD) in recent years. However, there is currently no commercial vaccine available to prevent CVA10 infection. Here we report the development of a recombinant virus-like particle (VLP) based candidate vaccine for CVA10. Co-expression of the capsid protein precursor P1 and the protease 3CD of CVA10 in Pichia pastoris resulted in cleavage of P1 into three capsid subunit proteins VP0, VP1, and VP3. These three subunit proteins co-assembled into CVA10 VLPs, which were visualized as spherical particles with a diameter of ∼30 nm under electron microscope. Immunization studies showed that CVA10 VLP could efficiently induce antigen-specific serum antibodies in mice. The anti-VLP sera were able to potently neutralize homologous and heterologous CVA10 strains. Importantly, passively transferred anti-VLP sera fully protected recipient neonatal mice from lethal CVA10 infection. In addition, neonatal mice born to the VLP-immunized dams were also completely protected from CVA10 lethal challenge. Collectively, these data show that CVA10 VLP represents a promising CVA10 vaccine candidate.

Yu Zhou

Chao Zhang

Qingwei Liu

Sitang Gong

Lanlan Geng

Zhong Huang

Antiviral research

ANTIVIRAL RESEARCH 发表关于控制人类和动物病毒感染的研究报告、简短通讯、评论文章和评论。其范围包括：抗病毒药物、抗体和宿主反应调节剂，包括它们的合成、体外和体内测试以及作用机制；针对人类病毒感染的新的或改进的疫苗；药物和疫苗安全性评估；耐药病毒或疫苗耐药病毒的进化和有效对策的制定；新药靶点的识别和验证；病毒性疾病的实验动物模型；病毒性疾病的发病机制和病毒逃避宿主免疫反应的机制。

The journal "Antiviral Research" publishes research reports, short communications, review articles, and commentaries on the control of human and animal viral infections. Its scope includes: antiviral drugs, antibodies, and host response modulators, including their synthesis, in vitro and in vivo testing, and mechanisms of action; new or improved vaccines for human viral infections; safety assessments of drugs and vaccines; the evolution of drug-resistant viruses or vaccine-resistant viruses and the development of effective countermeasures; identification and validation of new drug targets; experimental animal models of viral diseases; and mechanisms of viral diseases and how viruses evade host immune responses.

《Antiviral Research》期刊发表关于控制人类和动物病毒感染的研究报告、简短通讯、评论文章及综述。其研究范围包括：抗病毒药物、抗体及宿主反应调节剂的合成、体外和体内测试及作用机制；针对人类病毒感染的新型或改进疫苗；药物和疫苗的安全性评估；耐药病毒或疫苗耐药病毒的进化及有效对策的制定；新药靶点的识别与验证；病毒性疾病的实验动物模型；病毒性疾病的发病机制及病毒逃避宿主免疫反应的机制。

Antiviral Research

Antiviral Res

A virus-like particle vaccine protects mice against coxsackievirus A10 lethal infection.

Developing a recombinant virus‐like particle (VLP) based candidate vaccine for Coxsackievirus A10 showed that CVA10 VLP could efficiently induce antigen‐specific serum antibodies in mice, and passively transferred anti‐VLP sera fully protected recipient neonatal mice from lethal CVA 10 infection.

Category	Quartile
医学	2
医学, 药学	2
医学, 病毒学	2

A virus-like particle vaccine protects mice against coxsackievirus A10 lethal infection.

ivySCI AI Smartly Parses PDF, Answers Researchers' Questions, and Helps You Understand Papers in Seconds

Journal Info